CRBP Corbus Pharmaceuticals Holdings, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1595097 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-72.3%
TTM EPS YoY-10.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-131.5%
ROA-100.1%
ROIC (approx.)-160.1%
Asset turnover—
Leverage & solvency
Liabilities / assets31.0%
Debt / equity0.00x
Current ratio3.40x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-20.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $70.09M | $32.22M |
| SG&A expense | $15.21M | $16.50M |
| Operating income | -$85.31M | -$48.72M |
| Interest expense | $0 | $1.87M |
| Income tax | $0 | $0 |
| Net income | -$78.54M | -$40.21M |
| EBITDA | -$85.08M | -$48.13M |
| EPS (basic) | -5.90 | -3.68 |
| EPS (diluted) | -5.90 | -3.68 |
| Weighted avg. shares (diluted) | 13.32M | 10.92M |
| Balance sheet | ||
| Cash & equivalents | $28.49M | $17.20M |
| Short-term investments | $134.78M | $131.86M |
| Current assets | $166.95M | $152.98M |
| PP&E, net | $159,000 | $385,000 |
| Total assets | $168.19M | $155.88M |
| Current liabilities | $20.69M | $11.82M |
| Total liabilities | $20.69M | $13.45M |
| Shareholders' equity | $147.50M | $142.43M |
| Shares outstanding | 17.61M | 12.18M |
| Cash flow statement | ||
| Operating cash flow | -$64.49M | -$41.79M |
| Capital expenditure | $7,000 | $0 |
| Free cash flow | -$64.50M | -$41.79M |
| Investing cash flow | -$1.64M | -$121.31M |
| Financing cash flow | $77.43M | $166.58M |
| Depreciation & amortization | $233,000 | $588,000 |
| Stock-based compensation | $6.29M | $6.14M |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.